鼓室内与全身皮质类固醇激素一线治疗特发性突发性感音神经性聋的系统评价与Meta分析
该系统评价与Meta分析纳入7项随机研究共710例患者,比较鼓室内、全身及联合皮质类固醇激素一线治疗特发性突发性感音神经性聋的听力恢复情况。
要点
- 鼓室内皮质类固醇激素治疗并不优于全身治疗。
- 联合治疗未显示较单一治疗更好的听力结局。
- 证据基于7项随机研究共710例患者。
核心结论
- 本研究不支持鼓室内给予皮质类固醇激素比全身治疗对中重度特发性突发性感音神经性聋更有益。
- 没有迹象表明联合治疗较全身或鼓室内治疗能改善听力结局。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南,检索PubMed、Embase、OvidSP、CINAHL和Cochrane Library(1966年1月1日至2018年7月1日)。
- 纳入随机研究,共7项 eligible 研究,710例患者分配至鼓室内组(235例,33%)、全身组(325例,46%)或联合组(150例,21%)。
- 采用固定效应模型,主要结局为纯音平均听阈增益(dB)和恢复的比值比。
主要发现
- 联合组与鼓室内组比较的分析仅纳入2项研究。
关键数值与推荐
- 纳入研究须排除可识别病因,皮质类固醇激素须单独给药。
- 排除未将听力损失定义为72小时内至少30 dB的研究。
- 纯音平均听阈由4个频率的平均值计算:4项研究测500、1000、2000和3000 Hz,3项研究测500、1000、2000和4000 Hz。
临床怎么用
- 对于中重度特发性突发性感音神经性聋,一线治疗可选择全身皮质类固醇激素,鼓室内给药不作为更优推荐。
- 联合治疗未显示额外获益,临床决策需结合患者具体情况。
局限性
- 联合组与鼓室内组比较的分析仅基于2项研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To our knowledge, evidence-based recommendations on the intratympanic vs systemic administration of corticosteroids for the treatment of idiopathic sudden sensorineural hearing loss remain unestablished, and contradictory conclusions have been reported in previous meta-analyses. OBJECTIVE: To compare recovery from idiopathic sudden sensorineural hearing loss based on systemic, intratympanic, or a combined treatment with corticosteroids as first-line treatment. DATA SOURCES: We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We searched PubMed, Embase, OvidSP, CINAHL, and Cochrane Library from January 1, 1966, to July 1, 2018. This study was registered in the International Prospective Register of Systematic Reviews (CRD42018109314). STUDY SELECTION: We included randomized studies. Included studies must have excluded identifiable causes. Corticosteroids must have been administered solitarily. We excluded studies that did not define hearing loss as a minimum 30 dB within 72 hours. DATA EXTRACTION AND SYNTHESIS: We identified 170 titles, of which 56 (32.9%) were eligible for full-text screening. We independently extracted data. We applied a fixed-effects model to investigate our objectives. MAIN OUTCOMES AND MEASURE: We aimed to (1) estimate the difference in mean pure tone average (PTA) gain in decibels from intratympanic treatment vs systemic treatment and (2) investigate odds ratios for recovery between the different treatment groups. RESULTS: We included 7 eligible studies. A total of 710 patients were allocated to receive either intratympanic treatment (IT group, 235 [33%]), systemic treatment (ST group; 325 [46%]) or combined intratympanic and systemic treatment (CB group; 150 [21%]). The PTA was measured by taking the mean of 4 frequencies: 4 studies measured at 500, 1000, 2000, and 3000 Hz and 3 studies measured at 500, 1000, 2000, and 4000 Hz. The ST group had a 2.01-dB higher PTA gain (95% CI, -5.61 dB to 1.59 dB; P = .96; I2 = 0%) compared with the IT group and the odds for achieving complete recovery was not significantly different at an odds ratio of 0.94 (95% CI, 0.61 to 1.44; P = .19; I2 = 34.5%). For the CB group vs the ST group, the odds ratio was 1.11 (95% CI, 0.68 to 1.82; P = .75; I2 = 0%). The analysis of the CB group vs IT group comprised only 2 studies. CONCLUSIONS AND RELEVANCE: This study does not suggest that corticosteroid delivered intratympanically is more beneficial than systemic treatment in the case of moderate to severe idiopathic sudden sensorineural hearing loss. There were no indications that combined treatment was associated with improved hearing outcomes compared with either systemic or intratympanic treatment.
引用
- Mirian C, Ovesen T. Intratympanic vs Systemic Corticosteroids in First-line Treatment of Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32163109. doi:10.1001/jamaoto.2020.0047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。